Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Warning Letter
  6. /
  7. Beckman Coulter, Inc.
WARNING LETTER
•Beckman Coulter, Inc.•May 12, 2011

Beckman Coulter, Inc. – FDA Warning Letter, May 12, 2011

Record Details

An FDA inspection of Beckman Coulter, Inc. in Brea, California, from March 1 to May 12, 2011, revealed significant violations concerning the manufacture of Class II diagnostic chemistry analyzers and related products. The firm's devices were found to be adulterated under 21 U.S.C. § 351(h) due to non-conformity with Quality System (QS) regulation (21 CFR Part 820) and misbranded under 21 U.S.C. § 352(t)(2) for failing to provide information required by 21 U.S.C. § 360i and 21 CFR Parts 803 (Medical Device Reporting) and 806 (Reports of Corrections and Removals). Key QS violations included inadequate procedures for design changes, design validation, design plan review, personnel training, and corrective and preventive actions (CAPA), including insufficient documentation of CAPA activities. Medical Device Reporting deficiencies involved failures to report malfunctions within 30 days, submit all known information, implement written MDR procedures, and include required details like remedial actions and report sources. Additionally, the firm failed to report a correction and removal of its Synchron Systems LX-20/Unicel DxC ISE Reference Reagent to the FDA. The firm's response to the FDA 483 was deemed inadequate. Beckman Coulter must take prompt action to correct these violations and provide a written response within fifteen business days, detailing corrective actions, prevention plans, and a timeline. Failure to comply could result in severe regulatory actions, including seizure, injunction, civil money penalties, and impact on federal contracts, premarket approvals, and Certificates to Foreign Governments.

Company
Beckman Coulter, Inc.
Inspection date
May 12, 2011
Product type
Devices
Office
Los Angeles District Office
Person
  • Alonza E. Cruse (Director)
View Company Profile

ID · 5119ba85-d26c-4464-a625-daa6854d5672

Violation Codes10
21 U.S.C. 321(h)21 U.S.C. 351(h)21 CFR 82021 CFR 820.30(i)21 CFR 820.30(g)21 CFR 820.30(b)21 CFR 820.25(b)21 CFR 820.100(a)21 CFR 820.100(b)21 U.S.C. 360i

Full citation text and observation details available on the Dashboard.

Other documents for Beckman Coulter, Inc.
  • WARNING_LETTER - 2011-06-02June 2, 2011

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Beckman Coulter, Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.